The chemopreventive agent development research program in the Division of Cancer Prevention of the US National Cancer Institute: An overview
- 30 September 2005
- journal article
- review article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 41 (13), 1889-1910
- https://doi.org/10.1016/j.ejca.2005.04.016
Abstract
No abstract availableKeywords
This publication has 181 references indexed in Scilit:
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Stem cells and breast cancer: A field in transitNature Reviews Cancer, 2003
- Differential Expression of Estrogen Receptor β (ERβ) and Its C-Terminal Truncated Splice Variant ERβcx as Prognostic Predictors in Human Prostatic CancerBiochemical and Biophysical Research Communications, 2001
- Genistein Induces Apoptosis of RPE-J Cells by Opening Mitochondrial PTPBiochemical and Biophysical Research Communications, 2000
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Tamoxifen for the prevention of breast cancer: Pro:European Journal of Cancer, 2000
- The Hallmarks of CancerCell, 2000
- Influence of isoflavones in soy protein isolates on development of induced prostate‐related cancers in L‐W ratsNutrition and Cancer, 1997
- A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive TumorsNew England Journal of Medicine, 1989